Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. - Wikidata - awgldk - TriplyDB

Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.

Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q37854714

about

A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.

P2860

Q33431680-9657AAED-335E-4972-A777-07276127384D Q41674989-18DC22A0-320D-44D3-BB18-46655EF1BAC5

P2860

Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.

http://www.wikidata.org/entity/Q37854714

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.

@en

Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.

@nl

type

label

Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.

@en

Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.

@nl

prefLabel

Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.

@en

Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma.

@nl

P1433

Q37854714-7D960829-6C95-43D0-946D-E444F9640D44

P1476

Q37854714-23B1BEB2-3B72-4092-BAA5-4FF20B64B3BB

P2093

Q37854714-15425DC3-D0AA-4878-9D4C-13C78831A4E8

Q37854714-E3534469-2213-41EE-A3BB-388D4C77C988

P2860

Q37854714-0185FDA2-CC52-4E66-B4E1-1534591E09E1

Q37854714-06D3764D-57EC-4A7D-9787-D465E5EC7239

Q37854714-08F05E90-B64B-41BD-9DB5-DF0B04CF1BC5

Q37854714-0928C717-01DE-4709-A06A-DC153066891D

Q37854714-11282C7D-FC84-46A0-BEC8-B109F2D3DDBA

Q37854714-11891D38-9109-429C-A122-211C81AA7232

Q37854714-1209A7C9-F224-4024-98A1-3F9B4E5DB1B7

Q37854714-1365DCE1-E9C4-4412-A3E8-6B5C774E5680

Q37854714-1979CBE8-C5A7-4F09-8227-FE2CB2DFE219

Q37854714-1C8A4DFE-8776-4206-A3CF-431946AAE520

P304

Q37854714-79109DB1-215A-4E00-A163-025623051B77

P31

Q37854714-B0E1619C-49E1-4301-BE37-AE73E40A05E1

P356

Q37854714-2C86B12E-11DA-4817-85DF-A0468A0A74B8

P433

Q37854714-9ABF67D7-BF63-450E-9046-22183AFE9607

P478

Q37854714-52D11FAD-1487-46C6-8C66-F6AF0866BD1A

P50

Q37854714-6C4E8387-2C1A-4EC0-A128-F52F0134F5AC

Q37854714-E5E4277B-81F3-4E0F-98E3-9CFE1E76A85B

P577

Q37854714-ACB415C8-6B89-4A5B-A92F-F8BB013CD55F

P698

Q37854714-BEEF59F0-F71D-4327-8B23-95893C1BCF66

P921

Q37854714-9A82B07E-4D44-4348-BADC-5AAF50CD6FF3

Q37854714-FE6989EF-5EF7-4EB1-9AA4-D2E29E80EDDB

P356

P1433

Expert Review of Anticancer Therapy

P1476

Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma

@en

P2093

Ahmad S Halwani

http://www.w3.org/2001/XMLSchema#string

Brian K Link

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide and rituximab in Waldenstrom macroglobulinemia

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.

Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.

P304

443-455

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.11.9

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21417857

http://www.w3.org/2001/XMLSchema#string

P921